{"id":465,"date":"2026-08-28T06:56:05","date_gmt":"2026-08-28T06:56:05","guid":{"rendered":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/"},"modified":"2026-08-28T07:31:46","modified_gmt":"2026-08-28T07:31:46","slug":"ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/de\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/","title":{"rendered":"SS-31, Elamipretide und Forzinity: Warum die Unterscheidung zwischen Fertigarzneimitteln wichtig ist"},"content":{"rendered":"<p class=\"pim-standfirst wp-block-paragraph\">SS-31 und Elamipretid sind Namen, die f\u00fcr dasselbe auf Mitochondrien gerichtete Peptid verwendet werden, aber Forzinity ist ein spezifisches, von FDA zugelassenes Fertigarzneimittel mit einer genehmigten Anwendung, Formulierung, Herstellungskontrolle und Kennzeichnung. Ein \u00fcbereinstimmender Inhaltsstoffname stellt keine pharmazeutische \u00c4quivalenz her.<\/p><div class=\"wp-block-group pim-key-takeaways\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><h2 class=\"wp-block-heading\">Was die Aufzeichnung zeigt<\/h2><ul class=\"wp-block-list\"><li>Die zugelassene Indikation ist auf Patienten mit Barth-Syndrom mit einem Gewicht von mindestens 30 kg beschr\u00e4nkt.<\/li><li>Durch die beschleunigte Genehmigung entf\u00e4llt nicht das Erfordernis eines best\u00e4tigenden Nachweises.<\/li><li>Eine SS-31-Katalogcharge sollte durch ihre eigene Analyseaufzeichnung beschrieben werden, nicht durch \u00dcbernahme des Status des genehmigten Produkts.<\/li><\/ul><\/div><\/div><figure class=\"wp-block-image size-full pim-article-figure\"><img loading=\"lazy\" decoding=\"async\" width=\"1536\" height=\"1024\" src=\"http:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/mitochondrial-peptide-research-20260828.png\" alt=\"Wissenschaftler \u00fcberpr\u00fcft Bildgebungs- und Energiestoffwechseldaten der Mitochondrienmembran\" class=\"wp-image-458\" srcset=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/mitochondrial-peptide-research-20260828.png 1536w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/mitochondrial-peptide-research-20260828-300x200.png 300w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/mitochondrial-peptide-research-20260828-1024x683.png 1024w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/mitochondrial-peptide-research-20260828-768x512.png 768w\" sizes=\"auto, (max-width: 1536px) 100vw, 1536px\" \/><figcaption class=\"wp-element-caption\">Originale redaktionelle Illustration zur Identifizierung des Forschungsthemas. Es stellt keine Katalogcharge, kein zugelassenes Medikament, kein Testergebnis oder keine klinische Verwendung dar.<\/figcaption><\/figure><h2 class=\"wp-block-heading\">Die Identit\u00e4ts- und Beweisgrenze<\/h2><p class=\"wp-block-paragraph\">Die FDA-Anwendung umfasst produktspezifische Informationen zu Chemie, Herstellung, Sicherheit und Kennzeichnung. Nichts davon wird automatisch auf ein separates Material \u00fcbertragen, das den Namen Elamipretid oder SS-31 tr\u00e4gt.<\/p><div class=\"wp-block-group pim-evidence-table\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><div class=\"pim-evidence-row\"><strong>Zugelassenes Endprodukt<\/strong><span>Forzinity (Elamipretid)<\/span><\/div><div class=\"pim-evidence-row\"><strong>Anzeigegrenze<\/strong><span>Barth-Syndrom; K\u00f6rpergewicht mindestens 30 kg<\/span><\/div><div class=\"pim-evidence-row\"><strong>Forschungsmaterialaufzeichnung<\/strong><span>Reihenfolge, Form, Gehalt, Verunreinigungen und R\u00fcckverfolgbarkeit der Chargen<\/span><\/div><\/div><\/div><h2 class=\"wp-block-heading\">Was in die Materialakte geh\u00f6rt<\/h2><p class=\"wp-block-paragraph\">In einem Rechercheexemplar sollte angegeben werden, um welches Kataloglos es sich handelt und wie es getestet wurde. Es sollte nicht \u201eFDA-zugelassenes SS-31\u201c stehen, es sei denn, es geht um das zugelassene Endprodukt in seinem genauen regulatorischen Kontext.<\/p><h2 class=\"wp-block-heading\">Redaktionelle Regel<\/h2><p class=\"wp-block-paragraph\">Verwenden Sie den genauen Interventionsnamen, das Modell, die Population und den Endpunkt aus dem zitierten Datensatz. Wandeln Sie eine Assoziation, einen Mechanismus, ein Tierergebnis, eine genehmigte Fertigarzneimittelaufzeichnung oder einen analytischen Test nicht in einen Anspruch \u00fcber eine nicht verwandte Katalogcharge um.<\/p>","protected":false},"excerpt":{"rendered":"<p>SS-31 und Elamipretid sind Namen, die f\u00fcr dasselbe auf Mitochondrien gerichtete Peptid verwendet werden, aber Forzinity ist ein spezifisches, von FDA zugelassenes Fertigarzneimittel mit einer genehmigten Anwendung, Formulierung, Herstellungskontrolle und Kennzeichnung. Ein \u00fcbereinstimmender Inhaltsstoffname stellt keine pharmazeutische \u00c4quivalenz her.<\/p>","protected":false},"author":1,"featured_media":630,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"364","pim_article_type":"Evidence and material-quality guide","pim_evidence_level":"FDA label\/approval distinction and research-material quality review","pim_reviewer":"NHD evidence editorial workflow","pim_reviewed_date":"2026-08-28","pim_editorial_note":"Source-checked on 2026-08-28. Null findings and study limitations are retained. This is not independent peer review, medical advice, a customer case, or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"At least two linked primary or authoritative records and an explicit evidence boundary are present.","pim_creation_method":"The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.","pim_sources":"[{\"title\":\"FDA Drug Trials Snapshot: Forzinity\",\"url\":\"https:\/\/www.fda.gov\/drugs\/drug-trials-snapshots\/drug-trials-snapshots-forzinity\",\"note\":\"Trial population, endpoint results and approval basis.\"},{\"title\":\"Elamipretide phase 2\/3 Barth syndrome crossover trial\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33077895\/\",\"note\":\"Primary published trial; PMID 33077895.\"},{\"title\":\"FDA accelerated approval announcement for Forzinity\",\"url\":\"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-first-treatment-barth-syndrome\",\"note\":\"Approval scope and confirmatory requirement.\"}]","footnotes":""},"categories":[20],"tags":[],"class_list":["post-465","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-evidence-quality-guides"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.0 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>SS-31, Elamipretide and Forzinity: Why the Finished-Drug Distinction Matters - NHD<\/title>\n<meta name=\"description\" content=\"SS-31 and elamipretide are names used around the same mitochondrial-targeted peptide, but Forzinity is a specific FDA-approved finished drug with an approv\u2026\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/de\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SS-31, Elamipretide and Forzinity: Why the Finished-Drug Distinction Matters\" \/>\n<meta property=\"og:description\" content=\"SS-31 and elamipretide are names used around the same mitochondrial-targeted peptide, but Forzinity is a specific FDA-approved finished drug with an approv\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/de\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-28T06:56:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T07:31:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters-featured-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"1\u00a0Minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"SS-31, Elamipretide and Forzinity: Why the Finished-Drug Distinction Matters\",\"datePublished\":\"2026-08-28T06:56:05+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/\"},\"wordCount\":246,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters-featured-v2.webp\",\"articleSection\":[\"Evidence &amp; Quality Guides\"],\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/\",\"name\":\"SS-31, Elamipretide and Forzinity: Why the Finished-Drug Distinction Matters - NHD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters-featured-v2.webp\",\"datePublished\":\"2026-08-28T06:56:05+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"description\":\"SS-31 and elamipretide are names used around the same mitochondrial-targeted peptide, but Forzinity is a specific FDA-approved finished drug with an approv\u2026\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters-featured-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters-featured-v2.webp\",\"width\":1536,\"height\":960,\"caption\":\"Article-specific editorial image.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SS-31, Elamipretide and Forzinity: Why the Finished-Drug Distinction Matters\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/de\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"SS-31, Elamipretid und Forzinity: Warum die Unterscheidung zwischen Fertigarzneimitteln wichtig ist \u2013 NHD","description":"SS-31 und Elamipretid sind Namen, die f\u00fcr dasselbe auf Mitochondrien gerichtete Peptid verwendet werden, aber Forzinity ist ein spezifisches, von FDA zugelassenes Fertigarzneimittel mit einer zugelassenen \u2026","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/de\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/","og_locale":"de_DE","og_type":"article","og_title":"SS-31, Elamipretide and Forzinity: Why the Finished-Drug Distinction Matters","og_description":"SS-31 and elamipretide are names used around the same mitochondrial-targeted peptide, but Forzinity is a specific FDA-approved finished drug with an approv\u2026","og_url":"https:\/\/nhdbio.com\/de\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/","og_site_name":"NHD","article_published_time":"2026-08-28T06:56:05+00:00","article_modified_time":"2026-08-28T07:31:46+00:00","og_image":[{"width":1536,"height":960,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters-featured-v2.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"Verfasst von":"NHD Technical Team","Gesch\u00e4tzte Lesezeit":"1\u00a0Minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"SS-31, Elamipretide and Forzinity: Why the Finished-Drug Distinction Matters","datePublished":"2026-08-28T06:56:05+00:00","dateModified":"2026-08-28T07:31:46+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/"},"wordCount":246,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters-featured-v2.webp","articleSection":["Evidence &amp; Quality Guides"],"inLanguage":"de","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/","url":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/","name":"SS-31, Elamipretid und Forzinity: Warum die Unterscheidung zwischen Fertigarzneimitteln wichtig ist \u2013 NHD","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters-featured-v2.webp","datePublished":"2026-08-28T06:56:05+00:00","dateModified":"2026-08-28T07:31:46+00:00","description":"SS-31 und Elamipretid sind Namen, die f\u00fcr dasselbe auf Mitochondrien gerichtete Peptid verwendet werden, aber Forzinity ist ein spezifisches, von FDA zugelassenes Fertigarzneimittel mit einer zugelassenen \u2026","breadcrumb":{"@id":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters-featured-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters-featured-v2.webp","width":1536,"height":960,"caption":"Article-specific editorial image."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/ss-31-elamipretide-vs-forzinity-why-the-finished-drug-distinction-matters\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"SS-31, Elamipretide and Forzinity: Why the Finished-Drug Distinction Matters"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Peptidrohstoffe und individuelle Peptidsynthese","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"NHD Technisches Team","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"Das technische Team von NHD verwaltet Katalogdokumentationen und Beweiszusammenfassungen f\u00fcr Forschungszwecke. Rezensierte Artikel verweisen auf von Experten begutachtete Artikel, Studienregister und beh\u00f6rdliche Aufzeichnungen, behalten Nullergebnisse und Studieneinschr\u00e4nkungen bei und unterscheiden ver\u00f6ffentlichte Interventionen von Katalogmaterialien. F\u00fcr die Strukturierung kann AI-unterst\u00fctztes Zeichnen verwendet werden; Quellenverkn\u00fcpfungen und Beweisgrenzen bleiben sichtbar. Bei dieser Arbeit handelt es sich nicht um eine unabh\u00e4ngige Begutachtung oder medizinische Beratung.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/de\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/posts\/465","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/comments?post=465"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/posts\/465\/revisions"}],"predecessor-version":[{"id":511,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/posts\/465\/revisions\/511"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/media\/630"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/media?parent=465"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/categories?post=465"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/tags?post=465"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}